Inhibition of human colon cancer cell growth by antisense oligodeoxynucleotides targeted at basic fibroblast growth

P Netzer1, M Domek, R Pai

  • 1VA Medical Center, Long Beach, California, USA. peter.netzer@insel.ch

Abstract

Insights

Basic fibroblast growth factor stimulates colon cancer cell growth. Antisense oligodeoxynucleotides targeting basic fibroblast growth factor messenger RNA effectively inhibit HT-29 colon cancer cell proliferation, suggesting a potential therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Basic fibroblast growth factor (bFGF) is known to be mitogenic in colon cancer cell lines.
  • Antisense oligodeoxynucleotides targeting bFGF mRNA inhibit human malignant melanoma cell growth.
  • The efficacy of antisense oligodeoxynucleotide strategy for colon cancer cells remained unevaluated.

Purpose of the Study:

  • To investigate bFGF's role in stimulating HT-29 human colon cancer cell growth.
  • To determine the efficacy of antisense oligodeoxynucleotides in inhibiting HT-29 cell growth.

Main Methods:

  • Western blotting confirmed bFGF protein presence in HT-29 cells.
  • Cell growth was assessed via trypan blue exclusion after 2, 4, and 6 days of treatment.
  • Phosphorothioate-modified oligodeoxynucleotides targeting bFGF mRNA were used, with DOTAP cationic liposomes for enhanced cellular uptake.

Main Results:

  • bFGF dose-dependently stimulated HT-29 cell growth, with peak stimulation at 20 ng/mL.
  • Antisense oligodeoxynucleotide treatment significantly inhibited cell growth compared to sense controls (P=0.007).
  • The growth inhibition was reversed by adding 20 ng/mL of bFGF.

Conclusions:

  • Targeting bFGF mRNA with antisense oligodeoxynucleotides inhibits HT-29 human colon cancer cell growth.
  • This suggests a potential therapeutic application of bFGF-targeted antisense oligodeoxynucleotides for colon cancer treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...